Impact BioMedical, Inc
Impact Biomedical Inc. is a U.S.-based early-stage biopharmaceutical and wellness company that discovers, patents, and seeks to commercialize proprietary science through external partners. Its model centers on licensing, co-development, joint ventures, and selective direct sales across healthcare, consumer wellness, and air-purification products.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2022–2025
Liiketoiminta
Osuus liikevaihdostaPatented science and drug-discovery assets aimed at neurological, oncologic, inflammatory, antiviral, and antimicrobial uses.
Over-the-counter and direct-to-consumer wellness offerings, including Laetose and related formulations.
Celios-branded air purification technology sold through online and distributor channels.
Licensing, co-development, milestone, and royalty arrangements used to monetize patents and technologies.
Asiakkaat
The company sells primarily to commercial partners rather than end consumers, using licensing and co-development to monetize its intellectual property. Its customer base includes pharmaceutical companies, consumer packaged goods companies, food companies, and distributors that can commercialize its technologies. For its Celios product line, it also reaches retail and online buyers through third-party distribution channels.
Buy rights to IBO technologies for development and commercialization in exchange for milestones and royalties.
License wellness, ingredient, or formulation technologies for branded consumer products.
Purchase Celios air purification products for resale through online and third-party networks.
Collaborate on product development and commercialization to reduce funding and execution burden.
Strategia
The company’s strategy is to monetize its patent portfolio by pairing proprietary science with external partners that can fund development, manufacturing, and commercialization. Recent disclosures show a push to broaden the portfolio with Celios and other technologies while seeking a merger structure and capital to support a larger commercial platform. Management also emphasizes cost control and intellectual-property monetization to keep the business funded as a going concern.
The company lacks scale to self-fund broad development and relies on partners for monetization.
New assets can create faster revenue opportunities and diversify the IP base.
The company needs funding and a stronger operating base to continue development and commercialization.
Maantiede
Impact Biomedical is headquartered in the United States and conducts most of its business through U.S.-issued patents, U.S. corporate operations, and U.S.-based capital markets access. The company also states that it has patent coverage and pending applications in countries worldwide, which supports future international licensing and commercialization. Its current revenue disclosure is product-based rather than country-based, so geographic revenue concentration is not disclosed.
Riskit
Impact Biomedical is highly dependent on successful patent protection, partner execution, and access to capital, which makes the business model inherently speculative. Development, regulatory, and manufacturing risks are amplified because the company relies on third parties for clinical supplies and commercialization, while current revenue remains minimal. As an early-stage IP company, it also faces going-concern, dilution, and impairment risk if monetization efforts do not scale.
- Going-concern and financing riskVaikutus: KriittinenTodennäköisyys: Kohtalainen
The company has limited revenue and has stated it may need additional capital to continue operations.
Kohdistuu - Intellectual property challenge or lossVaikutus: KorkeaTodennäköisyys: Kohtalainen
The business depends on patents and trademarks to create licensing value and defend products.
Kohdistuu: Issued and pending patents in multiple jurisdictions
- Partner execution and commercialization failureVaikutus: KorkeaTodennäköisyys: Kohtalainen
Revenue depends on external partners agreeing to license, develop, and distribute products.
Kohdistuu - Regulatory and clinical development delaysVaikutus: KorkeaTodennäköisyys: Kohtalainen
Drug candidates require lengthy trials and regulatory review before commercialization.
Kohdistuu: Biopharmaceutical and antiviral programs
- Third-party manufacturing dependenceVaikutus: KeskitasoTodennäköisyys: Kohtalainen
The company does not internally manufacture drug candidates and relies on outside suppliers.
Kohdistuu: Clinical supplies and future product production
Kirjanpito
Harkinnanvaraiset erätThe company may recognize Celios retail sales differently from milestone or royalty income as partnerships develop.
Vaikutus: Affects timing and classification of revenue
The company has acquired technologies and IP whose value depends on future commercialization success.
Vaikutus: Can create large non-cash charges if expected cash flows weaken
The company disclosed debt conversion and fair value adjustments tied to DSS obligations.
Vaikutus: Can materially affect net loss and equity
As an early-stage public company, non-cash compensation and advisory costs can be significant.
Vaikutus: Influences operating expense run-rate and comparability
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Ocean Biomedical, Inc.
OCEA · Pharmaceutical Preparations
Biomerica, Inc
BMRA · In Vitro & In Vivo Diagnostic Substances
Connect Biopharma Holdings Ltd
CNTB · Pharmaceutical Preparations
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company focused on developing rademikibart, an antibody designed to target IL-4Rα for asthma and COPD.
BioScience Health Innovations, Inc.
BHIC · Services-Computer Processing & Data Preparation
Harvard Bioscience, Inc
HBIO · Laboratory Analytical Instruments
Harvard Bioscience designs, manufactures, and sells life-science research tools used in drug discovery, translational medicine, and preclinical testing.
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Päivitetty: 24.9.2026